J&J heralds 66% efficacy for single-dose shot, but falls short of mRNA rivals
J&J’s vaccine is 66% effective at preventing symptomatic Covid-19, the company announced Friday, falling short of the roughly 95% efficacy seen in two-dose mRNA vaccines but giving the world its first proven single-shot inoculation against the pandemic virus. The vaccine was 72% effective in the US.
The vaccine was 85% effective at preventing severe disease, J&J said. As of 28 days after dosing, the company saw no hospitalizations or deaths in the vaccine group in any region, a fact CSO Paul Stoffels emphasized on a call with reporters.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.